Many pharmaceutical teams cross the regulatory finish line only to hit a wall: market access demands a head-to-head comparison or real-world data that simply doesn’t exist.
Treating Evidence Generation Planning (EGP) as a reactive, late-stage checklist rather than an early strategic lever is a costly mistake. When evidence planning is framed too narrowly around regulatory approval, companies face crippling access delays, severe price pressure, and an expensive post-launch scramble to fill avoidable gaps.
What if you could build the right evidence into your clinical strategy from day one?
Discover how leading organizations are reframing EGP from a compliance hurdle into a powerful competitive differentiator. Plus, explore how to align your evidence strategy with payer, provider, and patient decision points to ensure faster market uptake and stronger pricing.
Author
Aidan Dineen, PhD is a Senior Director within EVERSANA’s Value & Evidence team with nearly a decade of experience supporting pharmaceutical and medical device manufacturers in the development of evidence strategies that enable successful…
Megan is a Vice President at EVERSANA, leading HEOR projects involving health economic modeling, value communications, literature reviews and reimbursement submission strategy. Megan has extensive research and writing experience in both academic and commercial…